Abstract
Background Sepsis is the third leading cause of death worldwide and the main cause of in-hospital mortality. Despite decades of research, sepsis remains a major challenge faced by patients, clinicians, and medical systems worldwide. Early identification and prediction of patients at risk of sepsis and adverse outcomes associated with sepsis are critical. In this work, we aimed to develop an artificial intelligence algorithm that can predict sepsis early.
Materials and Methods We developed a predictive model for sepsis using data from the Physionet Cardiology Challenge 2019 ICU database. Our cohort consisted of adult patients who were admitted to the ICU. Sepsis diagnoses were determined using the Sepsis-3 criteria. The model, built with the XGBoost algorithm, was designed to anticipate sepsis prior to the appearance of clinical symptoms. An internal validation was conducted using a hold-off test dataset to evaluate the AI model’s predictive performance.
Results We have developed the VIOSync Sepsis Prediction Index (SPI), an AI-based predictive model designed to forecast sepsis up to six hours before its clinical onset, as defined by Sepsis-3 criteria. The AI model, trained on a dataset comprising approximately 40,000 adult patients, integrates variables such as vital signs, laboratory data, and demographic information. The model demonstrated a high prediction accuracy rate of 97%, with a sensitivity of 87% and a specificity of 98% in predicting sepsis up to 6 hours before the onset. When compared to the established qSOFA score, which has a specificity of 89% for sepsis prediction, our VIOSync SPI algorithm significantly enhances predictive reliability, potentially reducing false positive rates by a factor of 5.5.
Conclusions The VIOSync SPI demonstrated superior prediction performance over current sepsis early warning scores and predictive algorithms for sepsis onset. To validate the generalizability of our method across populations and treatment protocols, external validation studies are essential.
Competing Interest Statement
SGL, VSD, and IAG are co-founders and shareholders of Aisthesis Medical Ltd.
Funding Statement
This study was funded by Aisthesis Medical Ltd.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used (or will use) ONLY openly available human data that were originally located at Physionet.org
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Figure 2 have been revised.
Data Availability
All data produced in the present work are contained in the manuscript
